(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2.40% $ 4.70
@ $5.26
Emitido: 14 feb 2024 @ 14:48
Retorno: -10.56%
Señal anterior: feb 14 - 09:31
Señal anterior:
Retorno: 2.24 %
Live Chart Being Loaded With Signals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...
Stats | |
---|---|
Volumen de hoy | 1.42M |
Volumen promedio | 1.65M |
Capitalización de mercado | 493.90M |
EPS | $0 ( 2024-04-01 ) |
Próxima fecha de ganancias | ( $-0.440 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.66 |
ATR14 | $0.00900 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Carson William H. | Buy | 3 200 | Common Stock |
2024-02-16 | Love Douglas | Buy | 656 200 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 160 000 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 39 000 | Common Stock |
2024-02-16 | Artis Dean Richard | Buy | 160 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
80.77 |
Last 94 transactions |
Buy: 9 088 380 | Sell: 879 119 |
Volumen Correlación
Annexon, Inc. Correlación
10 Correlaciones Más Positivas | |
---|---|
RMRM | 0.934 |
GTHX | 0.93 |
STKL | 0.913 |
NUTX | 0.91 |
EYE | 0.91 |
DXCM | 0.91 |
SDG | 0.909 |
EAR | 0.908 |
SVOK | 0.907 |
RRGB | 0.906 |
10 Correlaciones Más Negativas | |
---|---|
HDSN | -0.916 |
LCA | -0.9 |
MDWT | -0.896 |
NVCN | -0.89 |
SENEA | -0.885 |
OHAA | -0.882 |
HNRG | -0.879 |
ROKU | -0.878 |
IGTA | -0.877 |
FCBP | -0.877 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Annexon, Inc. Correlación - Moneda/Commodity
Annexon, Inc. Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-3.31M (0.00 %) |
EPS: | $-2.53 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-7.68 |
Financial Reports:
No articles found.
Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico